A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies
Akihiro Hirakawa1, Nolan A Wages2, Hiroyuki Sato3
1Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
Abstract:
Little is known about the relative performance of competing model-based dose-finding methods for combination phase I trials. In this study, we focused on five model-based dose-finding methods that have been recently developed. We compared the recommendation rates for true maximum-tolerated dose combinations (MTDCs) and over-dose combinations among these methods under 16 scenarios for 3 × 3, 4 × 4, 2 × 4, and 3 × 5 dose combination matrices. We found that performance of the model-based dose-finding methods varied depending on (1) whether the dose combination matrix is square or not; (2) whether the true MTDCs exist within the same group along the diagonals of the dose combination matrix; and (3) the number of true MTDCs. We discuss the details of the operating characteristics and the advantages and disadvantages of the five methods compared.
More Related Videos
Related Concept Videos
Clinical Trials: Overview
Bioavailability Study Design: Single Versus Multiple Dose Studies
Dosage Regimens: Designs and Approaches
Clinical Trials
There are four phases in a clinical trial. A phase one...
Dosage Regimen: Individualization
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...


